• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Why Cancer Registries are Part of America’s Fight for Racial Equality

by Warren A Whyte, Ph.D., VP Scientific Partnerships at ConcertAI 02/09/2021 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Warren A Whyte, Ph.D., VP Scientific Partnerships at ConcertAI

According to a 2019 study in the Proceedings of the National Academy of Sciences, one in 1,000 Black males can expect to die at the hands of the police. Black males were also 2.5 times more likely to die during an encounter with police than white males. For some, those figures are staggering. For many others, they are reminders of the racial disparities that have existed for far too long in this country.

So, in 2020, when recent events have brought racial injustice back into the national spotlight, it is important to take a closer look at all aspects of life where inequities exist – and not just in the criminal justice system.

Dr. John Carpten, chair of the department of translational genomics at Keck School of Medicine at USC, asked himself the same question as many Americans: what more could I be doing to better protect minorities?

“I know the Black Lives Matter movement is about police brutality and the killing of Black men, but Black lives should also matter when it comes to health equity,” he said at a forum in July. “So, I have a renewed purpose and a renewed charge to ensure that that happens.”

Carpten, who chairs the Minorities in Cancer Research Council at the American Association for Cancer Research, is among a growing cohort in the cancer research community (including myself) who are bringing an unprecedented focus on inequity in cancer care. 

The problem is clear: “Collectively, blacks have the highest death rate and shortest survival of any racial/ethnic group in the US for most cancers,” the American Cancer Society wrote this year. And we know that the reason for this gap is largely societal and structural, though there may also be biological factors at play.

But we need a deeper understanding of what is causing these differences, and where we can intervene to improve outcomes. 

Let’s get to work

Through my work, I have helped launch ERACE, or Engaging Research to Achieve Cancer Care Equity, which aims to bring the latest data, technology, and top US oncologists and cancer research centers together to create a race and ethnicity-based oncology registry. 

The registry is intended to generate insight into what is driving these inequalities, bring to bear positive outcomes for populations where disparities exist, and support the next generation of researchers in their search for innovative solutions.

We also believe that it will expand access for minority populations to cutting-edge cancer care. Although individuals from racial and ethnic backgrounds will comprise the majority of the U.S. population by 2040, they are consistently underrepresented in oncology clinical trials, comprising 1-5% of study participants. Building a national registry of minority cancer patients will address systemic geographic and structural barriers to achieve more equitable care and outcomes for all patients and not just the privileged few. 

The collective efforts that have recently launched to explicitly address these health inequities may finally move the needle in a positive direction. The National Foundation for Cancer Research is seeking funding to expand on genomic sequencing work led by Dr. Wei Zhang, director of cancer Genomics and precision oncology at Wake Forest Baptist Medical Center. Clinicians and scientists at Cold Spring Harbor Laboratory in New York announced new research efforts into “genetic contributions of ethnicity to the increased incidence of colon, endometrial, and pancreas cancers in African Americans.” 

And leading cancer research organizations like the Dana-Farber Cancer Institute are increasingly turning their attention and formidable resources to cancer disparities, both to better understand biological factors and to actively address the social forces that increase the risk for disease and limit access to treatment. 

It’s clear that the same forces behind movements such as Black Lives Matter are driving a commitment to change from the cancer research community. Now we need to hold ourselves accountable and make the case for more funding, for private-public partnerships, and for institutions to create space for their leading researchers to focus on this issue. 

Our words today will not be remembered. Our legacy will depend on whether the next generation inherits these racial disparities or not. 


About Warren A. Whyte, Ph.D.

Warren A Whyte, Ph.D., is the Vice President of Scientific Partnerships and Customer Success at ConcertAI where he responsible for working with internal and external stakeholders and customer-facing teams in healthcare to promote diversity and equity in cancer care and related services. Prior to ConcertAI, Whyte worked at Accenture where he led the strategic delivery of RWE offerings for leading drug and medical device companies across medical affairs, R&D, and commercial functions.

Prior to Accenture, Dr. Whyte consulted for several biopharmaceutical companies and led research in genomics and molecular biology that preceded the creation of Syros Pharmaceuticals, a venture-backed gene therapy company. Dr. Whyte has published in several peer-reviewed scientific journals. He has a BS in molecular and cell biology from Cornell University and a Ph.D. in genomics from MIT.


  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Accenture, American Cancer Society, biopharmaceutical, Black Lives Matter, cancer, Cancer ‘Moonshot’, Cancer Genomics, Clinical Trials, Diversity and Inclusion, gene therapy, Genomic Sequencing, genomics, Medical Device, Oncology, Patient Registry Market, Precision Oncology, risk

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |